STOCK TITAN

Kinnate Biopharma Inc - KNTE STOCK NEWS

Welcome to our dedicated news page for Kinnate Biopharma (Ticker: KNTE), a resource for investors and traders seeking the latest updates and insights on Kinnate Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kinnate Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kinnate Biopharma's position in the market.

-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.51%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
conferences
Kinnate Biopharma Inc

Nasdaq:KNTE

KNTE Rankings

KNTE Stock Data

124.99M
22.68M
0.16%
82.58%
0.99%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About KNTE

kinnate biopharma inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. the company's lead product candidate is kin002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. its other products in preclinical stage include kin003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (fgfr)2 and fgfr3 genes; and small molecule research programs, including a cyclin-dependent kinase 12 inhibitor in its kin004 program. kinnate biopharma inc. was founded in 2018 and is headquartered in san diego, california.